Preventive effect of LCZ696 on hypoxic pulmonary hypertension in rats via regulating the PI3K/AKT signaling pathway
Pulmonary Pharmacology & Therapeutics · 2023
DOI: 10.1016/j.pupt.2023.102229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pulmonary Pharmacology & Therapeutics, 2023. Verfasst von Jie Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Qinghai Provincial People 's Hospital Pharmacy Department, XiNing, China. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Pulmonary Fibrosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Hypoxic pulmonary hypertension (HPH) is a devastating disease worldwide; however, effective therapeutic drugs are lacking. This study investigated the effects and underlying mechanisms of LCZ696 treatment on hypoxia-induced pulmonary hypertension. Male Sprague-Dawley (SD) rats were kept in a hypobaric chamber with an oxygen concentration of 5% for 4 weeks. Rats were treated with either LCZ696 (18 mg/kg, 36 mg/kg, and 72 mg/kg) or sildenafil. The mean pulmonary artery pressure (mPAP), right ventricle hypertrophy index (RVHI), and lung system index were measured. Hematoxylin-eosin (HE) staining, Masson staining, and immunofluorescence staining were used for histological analysis. Enzyme linked immunosorbent assay (ELISA) kits were used to determine the concentrations of inflammatory and hypoxia-related factors. Western blotting was used to examine the expression of apoptotic and PI3K/AKT signaling pathway proteins in rat lung tissue. Hypoxia increased mPAP, RVHI, and lung system index and induced pulmonary vascular remodeling, pulmonary arteriomyosis, and pulmonary artery fibrosis. LCZ696 treatment reduced the increase in mPAP, RVHI, and the lung system index and ameliorated the induced pathological changes. Hypoxia upregulated expression of NF-kB, TNF-α, IL-6, HIF-1α, and Vascular endothelial growth factor (VEGF), decreased the ratio of Bax/Bcl-2, and activated the PI3K/AKT signaling pathway in lung tissue, and these effects were partially reversed by treatment with LCZ696. These results demonstrated that LCZ696 can ameliorate hypoxia-induced HPH by suppressing apoptosis, inhibiting the inflammatory response, and inhibiting the PI3K/AKT signaling pathway. It provides a reference for clinical rational drug use and lays a foundation for the study of HPH therapeutic drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Qinghai Provincial People 's Hospital Pharmacy Department, XiNing, China.
- Department of Pharmacy, First Clinical Hospital of Lanzhou University, Lanzhou, China.
- Medical College of Qinghai University, XiNing, China.
- Qinghai Provincial People 's Hospital Pharmacy Department, XiNing, China. Electronic address: wyf8289@163.com.
Zitieren
APA
Wang, J., Ma, Y. R., Chang, Y. E., Duo, D. L., Duan, K. K., Zhao, N., Cui, W. L., Huan, Z. L., & Wang, Y. F. (2023). Preventive effect of LCZ696 on hypoxic pulmonary hypertension in rats via regulating the PI3K/AKT signaling pathway. Pulmonary Pharmacology & Therapeutics. https://doi.org/10.1016/j.pupt.2023.102229
Vancouver
Wang J, Ma YR, Chang YE, Duo DL, Duan KK, Zhao N, et al. Preventive effect of LCZ696 on hypoxic pulmonary hypertension in rats via regulating the PI3K/AKT signaling pathway. Pulmonary Pharmacology & Therapeutics. 2023. doi:10.1016/j.pupt.2023.102229
BibTeX
@article{Wang2023,
author = {Wang, Jie and Ma, Yan-Rong and Chang, Ya-E and Duo, De-Long and Duan, Kun-Kun and Zhao, Ni and Cui, Wen-Li and Huan, Zhi-Lan and Wang, Ya-Feng},
title = {Preventive effect of LCZ696 on hypoxic pulmonary hypertension in rats via regulating the PI3K/AKT signaling pathway},
journal = {Pulmonary Pharmacology & Therapeutics},
year = {2023},
doi = {10.1016/j.pupt.2023.102229}
}
EUVIMED